CoChat
Sign Up
Cited by 68Cervical Cancer and HPV ResearchHealth Systems, Economic Evaluations, Quality of LifeGenital Health and Disease

HPV-FRAME: a consensus statement and quality framework for modelled evaluations of HPV-related cancer control

Open access
Canfell, Karen, Kim, Jane J., Kulasingam, Shalini, Berkhof, Johannes, Barnabas, Ruanne, Bogaards, Johannes A., Campos, Nicole, Jennett, Chloe +6 more·2019·Papillomavirus Research
DOI 10.1016/j.pvr.2019.100184PMC PMC6804684
Open this paper in CoChat — free accountOpen PDF

Abstract

Intense research activity in HPV modelling over this decade has prompted the development of additional guidelines to those for general modelling. A specific framework is required to address different policy questions and unique complexities of HPV modelling. HPV-FRAME is an initiative to develop a consensus statement and quality-based framework for epidemiologic and economic HPV models. Its development involved an established process. Reporting standards have been structured according to seven domains reflecting distinct policy questions in HPV and cancer prevention and categorised by relevance to a population or evaluation. Population-relevant domains are: 1) HPV vaccination in pre-adolescent and young adolescent individuals; 2) HPV vaccination in older individuals; 3) targeted vaccination in men who have sex with men; 4) considerations for individuals living with HIV and 5) considerations for low- and middle-income countries. Additional considerations applicable to specific evaluations are: 6) cervical screening or integrated cervical screening and HPV vaccination approaches and 7) alternative vaccine types and alternative dosing schedules. HPV-FRAME aims to promote the development of models in accordance with an explicit framework, to better enable target audiences to understand a model's strength and weaknesses in relation to a specific policy question and ultimately improve the model's contribution to informed decision-making.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pvr.2019.100184

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 111

  1. [2]de Martel C. Plummer M. Vignat J. Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type Int. J. Cancer 141 2017 664 670 28369882 PMC5520228
  2. [3]Novakovic D. Cheng A.T.L. Zurynski Y. Booy R. Walker P.J. Berkowitz R. A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program J. Infect. Dis. 217 2018 208 212 29136168
  3. [4]Marsico M. Mehta V. Chastek B. Liaw K.L. C Derkay C. Estimating the incidence and prevalence of juvenile-onset recurrent respiratory papillomatosis in publicly and privately insured claims databases in the United States Sex. Transm. Dis. 41 2014 300 305 24722383
  4. [5]Omland T. Akre H. Vårdal M. Brøndbo K. Epidemiological aspects of recurrent respiratory papillomatosis: a population-based study The Laryngoscope 122 2012 1595 1599 22565595
  5. [6]Lindeberg H. Elbrond O. Laryngeal papillomas: the epidemiology in a Danish subpopulation 1965-1984 Clin. Otolaryngol. 15 1991 125 131 2350888
  6. [7]Katsenos S. Becker H.D. Recurrent respiratory papillomatosis: a rare chronic disease, difficult to treat, with potential to lung cancer transformation: apropos of two cases and a brief literature review Case Rep. Oncol. 4 2011 162 171 21526134 PMC3081647
  7. [8]Brennan A. Akehurst R. Modelling in health economic evaluation. What is its place? What is its value? PharmacoEconomics 17 2000 445 459 10977387
  8. [9]Caro J. Briggs A.B. Siebert U. KM kuntz on behalf of the ISPOR-SMDM modelling good research practices task force, modelling good research practices—overview: a report of the ISPOR-SMDM modelling good research practices task force-1 Value Health 15 2012 796 803 22999128
  9. [10]Mendes D. Bains I. Vanni T. Jit M. Systematic review of model-based cervical screening evaluations BMC Canc. 15 2015 334 PMC4419493 25924871
  10. [11]Ben Hadj Yahia M.B. Jouin-Bortolotti A. Dervaux B. Extending the human papillomavirus vaccination programme to include males in high-income countries: a systematic review of the cost-effectiveness studies Clin. Drug Investig. 35 2015 471 485 26187455
  11. [12]Jiang Y. Gauthier A. Postma M.J. Ribassin-Majed L. Largeron N. Bresse X. A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus Hum. Vaccines Immunother. 9 2013 2285 2295 PMC3981835 23880955
  12. [13]Canfell K. Chesson H. Kulasingam S.L. Berkhof J. Diaz M. Kim J.J. Modelling preventative strategies against human papillomavirus-related disease in developed countries Vaccine 30 2012 F157 F167 23199959 PMC3783354
  13. [14]Jit M. Chapman R. Hughes O. Choi Y.H. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model BMJ 343 2011 d5775 21951758 PMC3181234
  14. [15]Seto K. Marra F. Raymakers A. Marra C.A. The cost effectiveness of human papillomavirus vaccines: a systematic review Drugs 72 2012 715 743 22413761
  15. [16]Brisson M. Van de Velde N. Boily M.C. Economic evaluation of human papillomavirus vaccination in developed countries Public Health Genom. 12 2009 343 351 19684446
  16. [17]Marra F. Cloutier K. Oteng B. Marra C. Ogilvie G. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review PharmacoEconomics 27 2009 127 147 19254046
  17. [18]Kim J.J. Kobus K.E. Diaz M. O'Shea M. Van Minh H. Goldie S.J. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy Vaccine 26 2008 4015 4024 18602731
  18. [19]Pitman R. Fisman D. S Zaric G. Postma M. Kretzschmar M. Edmunds J. Dynamic transmission modelling: a report of the ISPOR-SMDM modelling good research practices task force working group-5 Med. Decis. Mak. 32 2012 712 721 22990086
  19. [20]Jit M. Levin C. Brisson M. Levin A. Resch S. Berkhof J. Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts BMC Med. 11 2013 23 23363734 PMC3582485
  20. [21]Walker D.G. Hutubessy R. Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes Vaccine 28 2010 2356 2359 19567247
  21. [22]Ultsch B. Damm O. Beutels P. Bilcke J. Bruggenjurgen B. Gerber-Grote A. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community PharmacoEconomics 34 2016 227 244 26477039 PMC4766233
  22. [23]Craig B.M. Brisson M. Chesson H. Giuliano A.R. Jit M. Proceedings of the modelling evidence in HPV pre-conference workshop in Malmö, Sweden, may 9-10, 2009 Clin. Ther. 32 2010 1546 1564 20728767 PMC4095755
  23. [24]Moher D. Schulz K.F. Simera I I. Altman D.G. Guidance for developers of health research reporting guidelines PLoS Med. 7 2010 e1000217 PMC2821895 20169112
  24. [25]Vaccine Bosch F.X. Broker T.R. Schiffman M. Cuzick J. Meijer C.J.L.M. Sankaranarayanan R. Castellsague X. ICO Monograph, Comprehensive Control of HPV Infections and Related Diseases vol. 30 2012 F1 F202 Suppl 5
  25. [26]Kim S.Y. Goldie S.J. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches PharmacoEconomics 26 2008 191 215 18282015
  26. [28]Newall A.T. Beutels P. Wood J.G. Edmunds W.J. MacIntyre C.R. Cost-effectiveness analyses of human papillomavirus vaccination Lancet Infect. Dis. 7 2007 289 17376386
  27. [29]Jeronimo J. Castle P.E. Temin S. Denny L. Gupta V. Kim J.J. Secondary prevention of cervical cancer: ASCO resource-stratified clinical practice guideline J. Glob. Oncol. 3 2016 635 657 29094101 PMC5646891
  28. [30]World Health Organisation 2013 WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention http://apps.who.int/iris/bitstream/10665/94830/1/9789241548694_eng.pdf 24716265
  29. [31]Suijkerbuijk A.W. Donken R. Lugnér A.K. de Wit G.A. Meijer C.J. de Melker H.E. The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases Expert Rev. Vaccines 16 2017 361 375 27807989
  30. [32]Qendri V. Bogaards J.A. Berkhof J. Health and economic impact of a tender-based, sex-neutral human papillomavirus 16/18 vaccination program in The Netherlands J. Infect. Dis. 216 2017 210 219 28586466
  31. [33]Qendri V. Bogaards J.A. Berkhof J. Pricing of HPV vaccines in European tender-based settings Eur. J. Health Econ. 2018 10.1007/s10198-018-0996-9 PMC6439217 30051152 · DOI
  32. [34]Insinga R.P. Dasbach E.J. Elbasha E.H. Structural differences among cost-effectiveness models of human papillomavirus vaccines Expert Rev. Vaccines 7 2008 895 913 18767941
  33. [35]Brisson M. Bénard É. Drolet M. Bogaards J.A. Baussano I. Vänskä S. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models Lancet. Public Health. 1 2016 e8 e17 29253379 PMC6727207
  34. [36]Puig-Junoy J. Lopez-Valcarcel B.G. Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained Prev. Med. 48 2009 444 448 19232368
  35. [37]Jit M. Choi Y.H. Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom BMJ 337 2008 a769 18640957 PMC2500202
  36. [38]Bosch F.X. Robles C. Díaz M. Arbyn M. Baussano I. Clavel C. HPV-FASTER: broadening the scope for prevention of HPV-related cancer Nat. Rev. Clin. Oncol. 13 2016 119 132 26323382
  37. [39]Canfell K. Who should be vaccinated against HPV? BMJ 350 2015 h2244 25985329
  38. [40]Skinner S.R. Szarewski A. Romanowski B. Garland S.M. Lazcano-Ponce E E. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study Lancet 384 2014 2213 2227 25189358
  39. [41]Kim J.J. Brisson M. Edmunds W.J. Goldie S.J. Modelling cervical cancer prevention in developed countries Vaccine 26 2008 K76-K76 PMC2769256 18847560
  40. [42]Daling J.R. Madeleine M.M. Johnson L.G. Schwartz S.M. Shera K.A. Wurscher M.A. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer Cancer 101 2004 270 280 15241823
  41. [43]Daling J.R. Weiss N.S. Hislop T.G. Maden C. Coates R.J. Sherman K.J. Demarteau N. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer N. Engl. J. Med. 317 1987 973 977 2821396
  42. [44]Lin C. Franceschi S. Clifford G.M. Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis Lancet Infect. Dis. 18 2018 198 206 29158102 PMC5805865
  43. [45]Mooij S.H. van Santen D.K. Geskus R.B. van der Sande M.A. Coutinho R.A. Stolte I.G. The effect of HIV infection on anal and penile human papillomavirus incidence and clearance: a cohort study among MSM AIDS 30 2016 121 132 10.1097/QAD.0000000000000909 26474302 · DOI
  44. [46]D'Souza G. Wiley D.J. Li X. Chmiel J.S. Margolick J.B. Cranston R.D. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study J. Acquir. Immune Defic. Syndr. 48 2008 491 499 18614927 PMC3991563
  45. [47]Wilkin T.J. Chen H. Cespedes M.S. Leon-Cruz J.T. Godfrey C. Chiao E.Y. A randomized, placebo-controlled trial of the quadrivalent HPV vaccine in HIV-infected adults age 27 years or older: AIDS Clinical Trials Group protocol A5298 Clin. Infect. Dis. 67 2018 1339 1346 10.1093/cid/ciy274 29659751 PMC6186857 · DOI
  46. [48]Castellsagué X. Giuliano A.R. Goldstone S. Guevara A. Mogensen O. Palefsky J.M. Immunogenicity and safety of the 9-valent HPV vaccine in men Vaccine 33 2015 6892 6901 26144901
  47. [49]Palefsky J.M. Giuliano A.R. Goldstone S. Moreira E.D. Jr. Aranda C. Jessen H. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia N. Engl. J. Med. 365 2011 1576 1585 22029979
  48. [50]Lin A. Ong K.J. Hobbelen P. King E. Mesher D. Edmunds W.J. Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men Clin. Infect. Dis. 64 2016 580 588 10.1093/cid/ciw845 PMC5404831 28011615 · DOI
  49. [51]Phelan D.F. Gange S.J. Ahdieh-Grant L. Mehta S.H. Kirk G.D. Shah K. Determinants of newly detected human papillomavirus infection in HIV-infected and HIV-uninfected injection drug using women Sex. Transm. Dis. 36 2009 149 156 19174735 PMC2888629
  50. [52]Ahdieh L. Klein R.S. Burk R. Cu-Uvin S. Schuman P. Duerr A. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women J. Infect. Dis. 184 2001 682 690 11517428
  51. [53]Safaeian M. Kiddugavu M. Gravitt P.E. Gange S.J. Ssekasanvu J. Murokora D. Determinants of incidence and clearance of high-risk human papillomavirus infections in rural Rakai, Uganda Cancer Epidemiol. Biomark. Prev. 17 2008 1300 1307 PMC3158656 18559545
  52. [54]Hawes S.E. Critchlow C.W. Sow P.S. Toure P. N'Doye I. Diop A. Incident high-grade squamous intraepithelial lesions in Senegalese women with and without human immunodeficiency virus type 1 (HIV-1) and HIV-2 J. Natl. Cancer Inst. 98 2006 100 109 16418512
  53. [55]Schuman P. Ohmit S.E. Klein R.S. Duerr A. Cu-Uvin S. Jamieson D.J. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women J. Infect. Dis. 188 2003 128 136 12825181
  54. [56]Abraham A.G. D'Souza G. Jing Y. Gange S.J. Sterling T.R. Silverberg M.J. Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study J. Acquir. Immune Defic. Syndr. 62 2013 405 413 23254153 PMC3633634
  55. [57]Coghill A.E. Shiels M.S. Suneja G. Engels E.A. Elevated cancer-specific mortality among HIV-infected patients in the United States Clin. Oncol. 33 2015 2376 2383 10.1200/JCO.2014.59.5967 PMC4500831 26077242 · DOI
  56. [58]Dryden-Peterson S. Medhin H. Kebabonye-Pusoentsi M. Seage G.R. 3rd Suneja G. Kayembe M.K. Cancer incidence following expansion of HIV treatment in Botswana PLoS One 10 2015 e0135602 PMC4534370 26267867
  57. [59]Adler D.H. Kakinami L. Modisenyane T. Tshabangu N. Mohapi L. De Bruyn G. Increased regression and decreased incidence of human papillomavirus-related cervical lesions among HIV-infected women on HAART AIDS 26 2012 1645 1652 22555167 PMC3709565
  58. [60]Naud P.S. Roteli-Martins C.M. De Carvalho N.S. Teixeira J.C. de Borba P.C. Sanchez N. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination Hum. Vaccines Immunother. 10 2014 2147 2162 PMC4896780 25424918
  59. [61]Denn L. Hendricks B. Gordon C. Thomas F. Hezareh M. Dobbelaere K. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study Vaccine 31 2013 5745 5753 24091311
  60. [62]Kojic E.M. Kang M. Cespedes M.S. Umbleja T. Godfrey C. Allen R.T. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women Clin. Infect. Dis. 59 2014 127 135 24723284 PMC4305143
  61. [63]van Aar F. Mooij S.H. van der Sande M.A. Speksnijder A.G. Stolte I.G. Meijer C.J. Anal and penile high-risk human papillomavirus prevalence in HIV-negative and HIV-infected MSM AIDS 27 2013 2921 2931 23921617
  62. [64]Tobian A.A. Kigozi G. Gravitt P.E. Xiao C. Serwadda D. Eaton K.P. Human papillomavirus incidence and clearance among HIV-positive and HIV-negative men in sub-Saharan Africa AIDS 26 2012 1555 1565 22441255 PMC3442933
  63. [65]Grabowski M.K. Gray R.H. Serwadda D. Kigozi G. Gravitt P.E. Nalugoda F. High-risk human papillomavirus viral load and persistence among heterosexual HIV-negative and HIV-positive men Sex. Transm. Infect. 90 2014 337 343 24482488 PMC4030299
  64. [66]Palefsky J. Holly E. Hogeboom C. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intra-epithelial lesions in HIVpositive and HIV-negative homosexual men J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17 1998 314 319 9525431
  65. [67]Grulich A.E. van Leeuwen M.T. Falster M.O. Vajdic C.M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis Lancet 370 2007 59 67 17617273
  66. [68]Palefsky J.M. Holly E.A. Efirdc J.T. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men AIDS 19 2005 1407 1414 16103772
  67. [69]Piketty C. Cochand-Priollet B. Lanoy E. Lack of regression of anal squamous intraepithelial lesions despite immune restoration under cART AIDS 27 2013 401 406 23079803
  68. [70]Palefsky J.M. Holly E.A. Ralston M.L. Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection J. Acquir. Immune Defic. Syndr. 28 2001 422 428 11744829
  69. [71]Libois A. Feoli F. Nkuize M. Delforge M. Konopnicki D. Clumeck N. Prolonged antiretroviral therapy is associated with fewer anal high-grade squamous intraepithelial lesions in HIV-positive MSM in a cross-sectional study Sex. Transm. Infect. 93 2017 15 17 27030607
  70. [72]de Pokomandy A.I. Rouleau D. Ghattas G. Trottier H. Vézina S. Coté P. HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV Clin. Infect. Dis. 52 2011 1174 1181 10.1093/cid/cir064 21364075 · DOI
  71. [73]Liu G. Sharma M. Tan N. Barnabas R.V. HIV-positive women have higher risk of HPV infection, precancerous lesions, and cervical cancer: a systematic review and meta-analysis AIDS 32 2018 795 808 10.1097/QAD.0000000000001765 29369827 PMC5854529 · DOI · Paper page
  72. [74]Lam J.M. Hoch J.S. Tinmouth J. Sano M. Raboud J. Salit I.E. Cost-effectiveness of screening for anal precancers in HIV-positive men AIDS 25 2011 635 642 21139488
  73. [75]Czoski-Murray C. Karnon J. Jones R. Smith K. Kinghorn G. Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer Health Technol. Assess. 14 2010 1 101 iii-iv, ix-x 10.3310/hta14530 21083999 · DOI
  74. [76]Campos N.G. Tsu V. Jeronimo J. Mvundura M. Lee K. Kim J.J. To expand coverage, or increase frequency: quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings Int. J. Cancer 140 2017 1293 1305 27925175 PMC5516173
  75. [77]Campos N.G. Maza M. Alfaro K. Gage J.C. Castle P.E. Felix J.C. Cremer M.L. Kim J.J. The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador Int. J. Cancer 137 2015 893 902 25639903
  76. [78]Campos N.G. Castle P.E. Wright T.C. Jr. Kim J.J. Cervical cancer screening in low-resource settings: a cost-effectiveness framework for valuing tradeoffs between test performance and program coverage Int. J. Cancer 137 2015 2208 2219 25943074 PMC4910518
  77. [79]Goldie S.J. Gaffikin L. Goldhaber-Fiebert J.D. Gordillo-Tobar A. Levin C. Mahé C. Cost-effectiveness of cervical-cancer screening in five developing countries N. Engl. J. Med. 353 2005 2158 2168 16291985
  78. [80]Sharma M. Sy S. Kim J.J. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting BJOG 123 2016 917 926 26176301
  79. [81]Levin C.E. Sharma M. Olson Z. Verguet S. Shi J.F. Wang SM S.M. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China Vaccine 33 2015 2830 2841 25770785
  80. [82]Jit M. Brisson M. Portnoy A. Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study Lancet Glob. Health 2 2014 e406 e414 25103394
  81. [83]Kiatpongsan S. Kim J.J. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries PLoS One 9 2014 e106836 PMC4157790 25198104
  82. [84]Kim J.J. Campos N.G. O'Shea M. Diaz M. Mutyaba I. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa Vaccine 31 2013 60 72 24331749
  83. [85]Kim J.J. Sharma M. O'Shea M. Sweet S. Diaz M. Sancho-Garnier H. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA) Vaccine 31 2013 G65 G77 24331822
  84. [86]Berkhof J. Bogaards JA J.A. Demirel E. Diaz M. Sharma M. Kim J.J. Cost-effectiveness of cervical cancer prevention in central and Eastern Europe and central Asia Vaccine 31 Suppl 2013 H71 H79 24332299
  85. [87]Campos N.G. Kim J.J. Castle P.E. Ortendahl J.D. O'Shea M. Diaz M. Goldie S.J. Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa Int. J. Cancer 130 2012 2672 2684 21717458 PMC3314721
  86. [88]Sharma M. Ortendahl J. van der Ham E. Sy S. Kim J.J. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand BJOG 119 2012 166 176 21481160
  87. [89]Goldie S.J. Levin C. Mosqueira-Lovón N.R. Ortendahl J. Kim J. O'Shea M. Diaz Sanchez M. Mendoza Araujo M.A. Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru Rev. Panam. Salud Públic 32 2012 426 434 23370186
  88. [90]Canfell K. Shi J.F. Lew J.B. Walker R. Zhao F.H. Simonella L L. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies Vaccine 29 2011 2487 2494 21211586
  89. [91]Goldie S.J. Diaz M. Constenla D. Alvis N. Andrus J.K. Kim S.Y. Mathematical models of cervical cancer prevention in Latin America and the Caribbean Vaccine 26 2008 L59 L72 18945403
  90. [92]Goldie S.J. O'Shea M. Campos N.G. Diaz M. Sweet S. Kim S.Y. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries Vaccine 26 2008 4080 4093 18550229
  91. [94]Goldie S.J. Kim J.J. Kobus K. Goldhaber-Fiebert J.D. Salomon J. O'Shea M.K. Cost-effectiveness of HPV 16, 18 vaccination in Brazil Vaccine 25 2007 6257 6270 17606315
  92. [96]Campos N.G. Lince-Deroche N. Chibwesha C.J. Firnhaber C. Smith J.S. Michelow P. Cost-effectiveness of cervical cancer screening in women living with HIV in South Africa: a mathematical modelling study J. Acquir. Immune Defic. Syndr. 79 2018 195 205 29916959 PMC6143200
  93. [97]Lince-Deroche N. Phiri J. Michelow P. Smith J.S. Firnhaber C. Costs and cost effectiveness of three approaches for cervical cancer screening among HIV-positive women in Johannesburg, South Africa PLoS One 10 2015 e0141969 PMC4646665 26569487
  94. [98]Vanni T. Luz P.M. Grinsztejn B. Veloso V.G. Foss A. Mesa-Frias M. Legood R. Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country Int. J. Cancer 131 2012 E96 E104 21964797
  95. [99]Bertram M.Y. Lauer J.A. De Joncheere K. Edejer T. Hutubessy R. Kieny M.-P. Cost-effectiveness thresholds: pros and cons. Policy and practice WHO Bull. 94 2016 861 936 http://www.who.int/bulletin/volumes/94/12/15-164418/en/ PMC5153921 27994285
  96. [100]Canfell K. Cervical screening in HPV-vaccinated populations Climacteric 21 2018 227 234 10.1080/13697137.2018.1428296 29565690 · DOI
  97. [101]Naber S.K. Matthijsse S.M. Rozemeijer K. Penning C. de Kok I.M. van Ballegooijen M. Cervical cancer screening in partly HPV vaccinated cohorts - a cost-effectiveness analysis PLoS One 11 2016 e0145548 10.1371/journal.pone.0145548 PMC4732771 26824771 · DOI
  98. [102]Lew J.B. Simms K. Smith M. Lewis H. Neal H. Canfell K. Effectiveness modelling and economic evaluation of primary HPV screening for cervical cancer prevention in New Zealand PLoS One 11 2016 e0151619 PMC4871332 27187495
  99. [103]Kim J.J. Burger E.A. Sy S. Campos N.G. Optimal cervical cancer screening in women vaccinated against human papillomavirus J. Natl. Cancer Inst. 109 2016 pii: djw216 PMC5068562 27754955
  100. [104]Diaz M. de Sanjose S. Ortendahl J. O'Shea M. Goldie S.J. Bosch FX F.X. Cost-effectiveness of human papillomavirus vaccination and screening in Spain Eur. J. Cancer 46 2010 2973 2985 20638840
  101. [105]Coupe V.M. de Melker H.E. Snijders P.J. Meijer C.J. Berkhof J. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands Vaccine 27 2009 5111 5119 19567242
  102. [106]Goldhaber-Fiebert J.D. Stout N.K. Salomon J.A. Kuntz K.M. Goldie S.J. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination J. Natl. Cancer Inst. 100 2008 308 320 18314477 PMC3099548
  103. [107]Khan M.J. Castle P.E. Lorincz A.T. Wacholder S. Sherman M. Scott D.R. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice J. Natl. Cancer Inst. 97 2005 1072 1079 16030305
  104. [108]Gok M. Coupé V.M. Berkhof J. Verheijen R.H. Helmerhorst T.J. Hogewoning C.J. Snijders P.J. Meijer C.J. HPV16 and increased risk of recurrence after treatment for CIN Gynecol. Oncol. 104 2007 273 275 17157365
  105. [109]Simonella L. Canfell K. Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries Vaccine 33 2015 34 51 25171843
  106. [111]Demarteau N. Tang C.H. Chen H.C. Chen C.J. Van Kriekinge G. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan Value Health 15 2012 622 631 22867770
  107. [112]Ng S.S. Hutubessy R. Chaiyakunapruk N. Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination Vaccine 36 2018 2529 2544 10.1016/j.vaccine.2018.03.024 29625764 · DOI
  108. [113]Jit M. Laprise J.F. Choi Y.H. Brisson M. Fewer than three doses of HPV vaccine Lancet Oncol. 16 2015 e423 e424 26370345
  109. [114]Jit M. Brisson M. Laprise J.F. Choi Y.H. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model BMJ 350 2015 g7584 25567037 PMC4285892
  110. [115]Brisson M. Laprise J.F. Chesson H.W. Drolet M. Malagón T. Boily M.C. Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States J. Natl. Cancer Inst. 108 2015 pii: djv282 10.1093/jnci/djv282 PMC6745694 26438574 · DOI
  111. [116]Simms K.T. Smith M.A. Lew J.B. Kitchener H.C. Castle P.E. Canfell K. Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries Int. J. Cancer 139 2016 2771 2780 10.1002/ijc.30392 27541596 · DOI

Cited by

Sorted by citations

Authors
Canfell, K., Kim, J. J., Kulasingam, S., Berkhof, J., Barnabas, R., Bogaards, J. A., Campos, N., Jennett, C., Sharma, M., Simms, K. T., Smith, M. A., Velentzis, L. S., Brisson, M., & Jit, M.
Affiliations
  • The University of Sydney (AU)
  • Harvard University (US)
  • University of Minnesota (US)
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
  • University of Washington (US)
  • National Institute for Public Health and the Environment (NL)
  • Cancer Council NSW (AU)
  • The University of Melbourne (AU)
  • Centre de recherche du CHU de Québec-Université Laval (CA)
  • Public Health England (GB)
Corresponding author
Canfell, Karen
ORCID
Venue
Papillomavirus Research
Publisher
Elsevier BV
Published
2019-12
Volume
8
Pages
100184
ISSN
2405-8521 (ISSN-L)
DOI
10.1016/j.pvr.2019.100184
PMC
PMC6804684
OpenAlex
W2973171938
Cited by
68
References
5
Citations by year
2026: 5 · 2025: 12 · 2024: 7 · 2023: 16 · 2022: 10 · 2021: 5 · 2020: 11 · 2019: 2
FWCI
5.33
Type
journal article
Language
en
Open access
Licence
Locations
  • Papillomavirus Research (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
  • Rivm (National Institute for Public Health and the Environment) (submittedVersion)
  • The Sydney eScholarship Repository (The University of Sydney) (submittedVersion)
  • Rivm (National Institute for Public Health and the Environment) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
European Commission
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Surgery › Genital Health and Disease
Keywords
consensus statement, HPV vaccination, early adolescents, older adults, men who have sex with men, HIV, low- and middle-income countries, cervical cancer screening, dosing regimen, cancer prevention, reporting guidelines
MeSH terms
Adolescent, Age Factors, Uterine Cervical Neoplasms, Delivery of Health Care, Female, Humans, Male, Mass Screening, Models, Theoretical, Neoplasms, Vaccination, Homosexuality, Male, Papillomavirus Infections, Papillomavirus Vaccines, Early Detection of Cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review